
2012 Brazilian Society of Rheumatology Consensus on the management of comorbidities in patients with rheumatoid arthritis

[Rev Bras Reumatol 2012; 52(4):474-495]

Ivânio Alves Pereira, Licia Maria Henrique da Mota, Boris Afonso Cruz, Claiton Viegas Brenol,
Lucila Stange Rezende Fronza, Manoel Barros Bertolo, Max Victor Carioca de Freitas, Nilzio Antônio da Silva,
Paulo Louzada-Junior, Rina Dalva Neubarth Giorgi, Rodrigo Aires Corrêa Lima, Geraldo da Rocha Castelar Pinheiro

In Page 474, where it reads:

Rheumatology Service and Endocrinology Service of the Sabin Laboratório de Análises Clínicas; Hospital
Universitário de Brasília – HUB.

It should read:

Brazilian Society of Rheumatology - BSR.

In Page 476, where it reads:

Treatment with other DMARDs and biologics, such as the drugs of the anti-TNF class, and mainly with the
IL-6 receptor inhibitor (tocilizumab) have controlled inflammation and increased the previously reduced TC/
HDL associated with inflammation, without interfering with the atherosclerotic index, and without increasing
clinical cardiovascular events so far.⁴²⁻⁴⁵

It should read:

Treatment with other DMARDs and biologics, such as the drugs of the anti-TNF class, and mainly with the
IL-6 receptor inhibitor (tocilizumab) have controlled inflammation and increased the previously reduced
HDL and TC associated with inflammation, without interfering with the atherosclerotic index (TC/HDL),
and without increasing clinical cardiovascular events so far.⁴²⁻⁴⁵

In page 493:

Discount the reference below:

47. Peters MJ, Nurmohamed MT, Kitas GD, Sattar N. Statin treatment of rheumatoid arthritis: comment on
the editorial by Ridker and Solomon. *Arthritis Rheum* 2010; 62(1):302-3.

© 2012 Elsevier Editora Ltda. All rights reserved.